var data={"title":"Immune globulin (Intravenous, subcutaneous, and intramsucular): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Immune globulin (Intravenous, subcutaneous, and intramsucular): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/320543?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">see &quot;Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information&quot;</a> and <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-patient-drug-information\" class=\"drug drug_patient\">see &quot;Immune globulin (Intravenous, subcutaneous, and intramsucular): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513229\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Thrombosis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Thrombosis may occur with immune globulin products. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. For patients at risk of thrombosis, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Renal dysfunction and acute renal failure (excluding Hizentra, HyQvia, and Gammastan):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with immune globulin intravenous (IGIV) products. Patients predisposed to renal dysfunction include those with any degree of preexisting renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. (<b>Note: </b>The following products do not contain sucrose: Bivigam, Flebogamma  DIF, Gammagard Liquid, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam 5%, Octagam 10%, and Privigen.) For patients at risk of renal dysfunction or acute renal failure, administer immune globulin IV products at the minimum concentration dose and infusion rate practicable. Ensure adequate hydration in patients before administration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513233\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bivigam;</li>\n      <li>Carimune NF;</li>\n      <li>Cuvitru;</li>\n      <li>Flebogamma DIF;</li>\n      <li>GamaSTAN S/D;</li>\n      <li>Gammagard;</li>\n      <li>Gammagard S/D Less IgA;</li>\n      <li>Gammagard S/D [DSC];</li>\n      <li>Gammaked;</li>\n      <li>Gammaplex;</li>\n      <li>Gamunex-C;</li>\n      <li>Hizentra;</li>\n      <li>Hyqvia;</li>\n      <li>Octagam;</li>\n      <li>Privigen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513234\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cuvitru;</li>\n      <li>Gamastan S/D;</li>\n      <li>Gammagard Liquid;</li>\n      <li>Gammagard S/D;</li>\n      <li>Gamunex;</li>\n      <li>Hizentra;</li>\n      <li>IGIVnex;</li>\n      <li>Octagam 10%;</li>\n      <li>Panzyga;</li>\n      <li>Privigen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13307640\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Blood Product Derivative</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Immune Globulin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13307724\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not all products are interchangeable with regards to route of administration; consult manufacturers' labeling for additional information. Consider osmolarity and concentration during product selection; infuse as slowly as indication and stability allow (see &quot;Immune Globulin Product Comparison&quot; section in Appendix for details). Dosage expressed as mg/kg or mL/kg dependent upon route of administration; use extra precaution to ensure accuracy. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Immune thrombocytopenia (ITP):</b> IV: 400 to 1000 mg/kg/day for 2 to 5 consecutive days (total dose: 2000 mg/kg); maintenance dose: 400 to 1000 mg/kg/dose every 3 to 6 weeks based on clinical response and platelet count </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Isoimmune hemolytic disease (Rh-incompatibility):</b> IV: GA &ge;35 weeks: 500 to 1000 mg/kg/dose once over 2 hours; if needed, dose may be repeated in 12 hours; most effective when administered as soon as possible after diagnosis (AAP Subcommittee on Hyperbilirubinemia, 2004; Girish, 2008; Gottstein, 2003; Miqdad, 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Measles, prophylaxis</b> (CDC, 2013): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pre-exposure prophylaxis (eg, during an outbreak, travel to endemic area): Immunocompromised patients: IV: &ge;400 mg/kg/dose within 3 weeks before anticipated exposure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Postexposure prophylaxis: Any neonate without evidence of measles immunity: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: 0.5 <b>mL</b>/kg/dose within 6 days of exposure; <b>Note:</b> Not all immune globulin preparations may be administered by the IM route; of the products currently available on the market, GamaSTAN S/D may be given IM; consult product labeling for additional information as market availability may change.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 400 mg/kg/dose within 6 days of exposure </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myasthenia gravis (severe exacerbation):</b> IV: 400 to 1000 mg/kg/dose once daily over 2 to 5 days for a total dose of 2000 mg/kg; if additional therapy required, dose should be based on clinical response and titrated to minimum effective dose (Bassan, 1998; Feasby, 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myocarditis, acute:</b> IV: 2000 mg/kg as a single dose. A cohort study of 21 young patients, including neonates, showed improvement in LVF recovery and survival at 1 year as compared to untreated historical cohort (Drucker, 1994); efficacy results are variable (English, 2004; Hia, 2004; Klugman, 2010); the largest data analysis did not show clear clinical benefit nor positive impact on survival (Klugman, 2010). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sepsis, adjunctive treatment:</b> IV: Limited data available; efficacy results variable: Usual dose: 500 to 1000 mg/kg/dose once daily for 1 to 3 days (Jenson, 1997; Ohlsson, 2010). The largest trial, INIS (n=3493), reported no difference in outcomes (including incidence of subsequent sepsis, death, or major disability at 2 years) between treatment and control groups using 500 mg/kg/day for 2 days (INIS Collaborative Group, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13307648\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">see &quot;Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not all products are interchangeable with regards to route of administration; consult manufacturers' labeling for additional information. Product-specific dosing is provided where applicable; some clinicians use ideal body weight or an adjusted ideal body weight in morbidly-obese patients to calculate an IVIG dose (Siegel 2010; Wimperis 2011). Dosage expressed as mg/kg or mL/kg and is dependent upon route of administration; use extra precaution to ensure accuracy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute disseminated encephalomyelitis (ADEM):</b> Limited data available: Children and Adolescents: IV: 1,000 mg/kg/dose once daily for 2 days (Feasby 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Colitis due to <i>Clostridium difficile</i>, chronic:</b> Limited data available: Infants and Children: IV: 400 mg/kg/dose every 3 weeks resulted in resolution of colitis symptoms during treatment; duration of therapy was unclear (n=5; age range: 6 to 37 months) (Abougergi 2011; Leung 1991; McFarland 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dermatomyositis, refractory:</b> Limited data available: Children: IV: 1,000 mg/kg/dose once daily for 2 days; <b>Note:</b> If maintenance therapy is required, the dose and frequency should be based on clinical response and doses should not exceed 2,000 mg/kg per treatment course (Feasby 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Guillain-Barr&eacute; syndrome:</b> Various regimens have been used: Limited data available: Children: IV: 1,000 mg/kg/dose once daily for 2 days (Feasby 2007; Korinthenberg 2005) <b>or</b> 400 mg/kg/dose once daily for 5 days (El-Bayoumi 2011; Korinthenberg 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hematopoietic cell transplantation (HCT) with hypogammaglobulinemia (IgG &lt;400 mg/dL), prevention of bacterial infection</b> (Tomblyn 2009): <b>Note:</b> Increase dose or frequency to maintain IgG concentration &gt;400 mg/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Within first 100 days after HCT: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children (Allogeneic HCT recipients): IV: 400 mg/kg/dose once monthly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: IV: 500 mg/kg/dose once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>&gt;100 days after HCT:</i> Infants, Children, and Adolescents: IV: 500 mg/kg/dose every 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatitis A, prophylaxis:</b> Infants, Children, and Adolescents: <b>Note:</b> Hepatitis A vaccine preferred for patients 12 months to 40 years (CDC 2017): <b>Note:</b> In adults, total dose volumes &gt;10 mL should be split into multiple injections given at different sites; in pediatric patients, consider splitting doses &lt;10 mL based on patient size.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Pre-exposure prophylaxis upon travel into endemic areas (CDC 2017): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Anticipated duration of risk &le;1 month: IM: 0.1 <b>mL</b>/kg/dose as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Anticipated duration of risk 1 to 2 months: IM: 0.2 <b>mL</b>/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Anticipated duration of risk &ge;2 months: IM: 0.2 <b>mL</b>/kg/dose every 2 months</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Postexposure prophylaxis:</i> IM: 0.1 <b>mL</b>/kg/dose as a single dose given within 14 days of exposure and prior to manifestation of disease; not needed if at least 1 dose of hepatitis A vaccine was given at &ge;1 month before exposure (CDC 2006; CDC 2007; CDC 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV infection </b>(HHS [OI pediatric 2016]): Infants and Children:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Primary prophylaxis for serious bacterial infection in patients with hypogammaglobulinemia (IgG &lt;400 mg/dL):</i> IV: 400 mg/kg/dose every 2 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Secondary prophylaxis for invasive bacterial infections:</i> Should only be used if subsequent infections are frequent severe infections (&gt;2 infections during a 1-year period): IV: 400 mg/kg/dose every 2 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Immune thrombocytopenia (ITP): </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">General dosing: <b>Note:</b> Dosing regimens variable, consult product specific information if available: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Acute therapy: IV: 400 to 1,000 mg/kg/dose once daily for 2 to 5 consecutive days for a total cumulative dose of 2,000 mg/kg; in some cases, cumulative doses up to 3,000 mg/kg have been used</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Chronic therapy: IV: 400 to 1,000 mg/kg/dose every 3 to 6 weeks based on clinical response and platelet count</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Carimune NF: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Acute therapy: IV: 400 mg/kg/dose once daily for 2 to 5 days to maintain platelet count &ge;30,000/mm<sup>3</sup> and/or to control significant bleeding. If platelet response is adequate (30,000 to 50,000/mm<sup>3</sup>) after the first 2 doses, then may discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Chronic therapy: IV: 400 mg/kg/dose as a single infusion; may increase to 800 to 1,000 mg/kg/dose to maintain platelet count &ge;30,000/mm<sup>3</sup> and/or to control significant bleeding</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Flebogamma DIF 10%: Children &ge;2 years and Adolescents: Chronic therapy: IV: 1,000 mg/kg/dose once daily for 2 consecutive days</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">Gammaked: Infants, Children, and Adolescents: Acute or chronic therapy: IV: 400 to 1,000 mg/kg/dose once daily for 2 to 5 consecutive days for a total cumulative dose of 2,000 mg/kg; if an adequate platelet response is observed after the initial 1,000 mg/kg/dose, then the subsequent dose may be held</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Gamunex-C: Infants, Children, and Adolescents: Acute or chronic therapy: IV: 1,000 mg/kg/dose once daily for 1 to 2 days based on patient response and/or platelet response or for fluid-restricted patients or other conditions sensitive to volume: 400 mg/kg once daily for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Privigen: Adolescents &ge;15 years: Chronic therapy: IV: 1,000 mg/kg/dose once daily for 2 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Kawasaki disease:</b> Infants and Children: IV: 2,000 mg/kg as a single dose over 10 to 12 hours; usually given within 10 days of disease onset; however, may be given &gt;10 days from onset in patients with delayed diagnosis or with persistent symptoms of systemic inflammation with persistent fever and/or coronary artery aneurysms; must be used in combination with aspirin; if signs and symptoms persist &ge;36 hours after completion of the infusion, retreatment with a second 2,000 mg/kg infusion may be considered with or without corticosteroids. <b>Note: </b>Corticosteroids may be added for primary treatment in patients identified as high risk for development of coronary artery aneurysms (AHA [McCrindle 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Measles, prophylaxis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Pre-exposure prophylaxis (eg, during an outbreak, travel to endemic area): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: Patients with primary humoral immunodeficiency:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: Gammaked, Gamunex-C (Infants, Children, and Adolescents), Octagam 5% (Children and Adolescents, 6 to 16 years): &ge;400 mg/kg/dose immediately before expected exposure; <b>Note:</b> Should only administer to patients whose routine dose is &lt;400 mg/kg/dose.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">SubQ infusion: Hizentra: Children &ge;2 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weekly dosing: &ge;200 mg/kg/dose once weekly for 2 consecutive weeks</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Biweekly dosing: &ge;400 mg/kg for 1 dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing: ACIP recommendations (CDC 2013): Immunocompromised patients: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: &ge;400 mg/kg/dose within 3 weeks before anticipated exposure</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">SubQ: 200 mg/kg/dose once weekly for 2 consecutive weeks prior to anticipated exposure (CDC 2013); <b>Note:</b> Not all immune globulin preparations may be administered by the SubQ route; Hizentra is the only product currently approved for this indication that may be administered SubQ; consult product labeling for additional information as market availability may change</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Postexposure prophylaxis: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: Patients with primary humoral immunodeficiency:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: Gammaked, Gamunex-C (Infants, Children, and Adolescents), Octagam 5% (Children and Adolescent, 6 to 16 years): 400 mg/kg/dose administered as soon as possible after exposure</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">SubQ infusion: Hizentra: Children &ge;2 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weekly dosing: &ge;200 mg/kg/dose as soon as possible following exposure</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Biweekly dosing: &ge;400 mg/kg as soon as possible following exposure</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternate dosing: ACIP guidelines (CDC 2013): Any person without evidence of measles immunity: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">IM: 0.5 <b>mL</b>/kg/dose; maximum dose: 15 mL within 6 days of exposure; in adults, doses &gt;10 mL should be split into multiple injections and administered at different sites; in pediatric patients, may also split doses &lt;10 mL based on patient size. <b>Note:</b> Not all immune globulin preparations may be administered by the IM route; of the products currently available on the market, GamaSTAN S/D may be given IM; consult product labeling for additional information as market availability may change. GamaSTAN S/D manufacturer labeling suggests a lower IM dose of 0.25 <b>mL</b>/kg; however, this dosing was based on previous immune globulin donor potency concentrations; recent data indicates that potency from current donor populations has decreased (ie, measles immunity now from vaccinations instead of immunity from disease) requiring a higher IM immune globulin dose (0.5 <b>mL</b>/kg) in all patients without evidence of measles immunity to ensure adequate serum titers.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">IV: 400 mg/kg/dose within 6 days of exposure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Multiple sclerosis (relapsing-remitting, when other therapies cannot be used):</b> Limited data available: Children and Adolescents: Dosage regimen variable; optimal dose not established: IV: 1,000 mg/kg/dose once monthly, with or without an induction of 400 mg/kg/day for 5 days (Feasby 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Myasthenia gravis, severe exacerbation:</b> Limited data available: Children: IV: 400 to 1,000 mg/kg/dose once daily over 2 to 5 days for a total dose of 2,000 mg/kg; if additional therapy required, dose should be based on clinical response and titrated to minimum effective dose (Feasby 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Myocarditis, acute:</b> Limited data available: Infants, Children, and Adolescents: IV: 2000 mg/kg as a single dose. A cohort study of 21 children showed improvement in LVF recovery and survival at 1 year as compared to untreated historical cohort (Drucker 1994); efficacy results are variable (English 2004; Hia 2004; Klugman 2010); the largest data analysis did not show clear clinical benefit nor positive impact on survival (Klugman 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary immunodeficiency disorders:</b> Adjust dose/frequency based on desired IgG concentration and clinical response; a trough IgG concentration of &ge;500 mg/dL has been recommended by some experts (Bonilla 2005); consult product specific labeling for appropriate age groups.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">General dosing: Infants, Children, and Adolescents: 200 to 800 mg/kg/dose every 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Carimune NF: Infants, Children, and Adolescents: 400 to 800 mg/kg/dose every 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Flebogamma DIF 5%, Gammagard Liquid, Gammagard S/D (Children &ge;2 years and Adolescents), Gammaked, Gamunex-C (Infants, Children, and Adolescents), Octagam 5% (Children and Adolescents 6 to 16 years): 300 to 600 mg/kg/dose every 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Bivigam (Children &ge;6 years and Adolescents), Gammaplex 5% (Children &ge;2 years and Adolescents): 300 to 800 mg/kg/dose every 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Privigen: Children &ge;3 years and Adolescents: 200 to 800 mg/kg/dose every 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">SubQ infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Cuvitru: Children &ge;2 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Patients switching from IGIV therapy</i>: Begin 1 week after last immune globulin IV dose. Use the following equations to calculate initial dose:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Initial weekly dosing: Dose (grams) = (IV dose [grams] divided by IV dose interval [weeks]), then multiply this dose by 1.3 (dose adjustment factor)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Biweekly dosing (grams): Multiply the calculated weekly dose by 2</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Frequent dosing (2 to 7 times per week) (grams): Divide the calculated weekly dose by the desired number of times per week</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Patients switching from another IG SubQ product:</i> SubQ infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weekly dosing (grams): Weekly dose is the same as the prior immune globulin subcutaneous weekly dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Biweekly dosing (grams): Multiply the calculated weekly dose by 2</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Frequent dosing (2 to 7 times per week) (grams): Divide the calculated weekly dose by the desired number of administration times per week</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Gammagard Liquid, Gammaked, Gamunex-C: Children &ge;2 years and Adolescents: Begin 1 week after last IV dose. Use the following equation to calculate initial dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Initial weekly dose: Dose (grams) = (1.37 x IV dose [grams]) divided by (IV dose interval [weeks]); <b>Note:</b> For subsequent doses, refer to product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hizentra: Children &ge;2 years and Adolescents: For weekly dosing or frequent (up to daily), begin 1 week after last IV or SubQ infusion. For biweekly dosing, begin 1 or 2 weeks after last IV infusion or 1 week after the last SubQ weekly infusion. <b>Note:</b> Patient should have received an IV immune globulin routinely for at least 3 months before switching to SubQ. Use the following equation to calculate initial dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Initial <b>weekly</b> dose: Dose (grams) = (Previous IV dose [grams]) divided by (IV dose interval [weeks]) then multiply by 1.37; if switching from a different SubQ formulation to Hizentra, maintain previous weekly SubQ dose initially. <b>Note:</b> To convert the dose (in grams) to mL, multiply the calculated dose (in grams) by 5.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note:</b> Provided the total weekly dose is maintained, any dosing interval from daily up to biweekly (every 2 weeks) may be used. Use the following calculations to calculate frequent or biweekly dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Biweekly dose (grams): Dose = Calculated or previous weekly SubQ dose (grams) multiplied by 2</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Frequent (2 to 7 times per week) dosing: Dose (grams) = Calculated or previous weekly dose (grams) divided by the desired number of times per week (eg, for 3 times per week dosing, divide weekly dose by 3)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note:</b> For subsequent doses refer to product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rubella, prophylaxis during pregnancy (postexposure):</b> GamaSTAN S/D: Adolescents: IM: 0.55 <b>mL</b>/kg/dose as a single dose within 72 hours of exposure (Watson 1998); <b>Note:</b> Not recommended for routine use; may reduce, but not eliminate, risk for rubella. In adults, total dose volumes &gt;10 mL should be split into multiple injections given at different sites.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN):</b> Limited data available: Infants, Children, and Adolescents: IV: Usual dose: 1500 to 2000 mg/kg total dose as a single dose or divided over 2 to 4 days; dosing based on retrospective reviews and case reports; efficacy results are variable (Koh 2010; Morici 2000; Tristani-Firouzi 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Varicella-zoster, postexposure prophylaxis (independent of HIV-status):</b> Infants, Children, and Adolescents: <b>Note:</b> Use only if varicella-zoster immune globulin is unavailable.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 400 mg/kg as a single infusion as soon as possible and within 10 days of exposure; ideally within 96 hours of exposure (HHS [OI pediatric 2016]; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: GamaSTAN S/D: 0.6 to 1.2 <b>mL</b>/kg/dose as a single dose within 72 hours of exposure (Gershon 1978); <b>Note:</b> In adults, injections &gt;10 mL should be split into multiple injections given at different sites; in pediatric patients, consider splitting doses &lt;10 mL based on patient size.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>B-cell chronic lymphocytic leukemia (CLL)</b>\n      <b> with hypogammaglobulinemia, prevention of bacterial infections<b>:</b></b> Gammagard S/D: IV: 400 mg/kg/dose every 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic inflammatory demyelinating polyneuropathy (CIDP):</b> Gammaked, Gamunex-C, Privigen: IV: Loading dose: 2,000 mg/kg (given in divided doses over 2 to 4 consecutive days); Maintenance: 1,000 mg/kg every 3 weeks. Alternatively, administer 500 mg/kg/day for 2 consecutive days every 3 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatitis A:</b> GamaSTAN S/D: IM:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Preexposure prophylaxis upon travel into endemic areas (hepatitis A vaccine preferred):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">0.1 <b>mL</b>/kg for anticipated risk of exposure &lt;1 month</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">0.2 <b>mL</b>/kg for anticipated risk of exposure &lt;2 months; repeat every 4 to 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Repeat dose of 0.2 <b>mL</b>/kg every 2 months anticipated risk of exposure &gt;2 months</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Postexposure prophylaxis:</i> 0.1 <b>mL</b>/kg given within 14 days of exposure and/or prior to manifestation of disease; not needed if at least 1 dose of hepatitis A vaccine was given at &ge;1 month before exposure (CDC 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Immune thrombocytopenia (ITP):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Carimune NF: IV: Initial: 400 mg/kg/day for 2 to 5 consecutive days; Maintenance: 400 mg/kg as needed to maintain platelet count &ge;30,000/mm<sup>3</sup> and/or to control significant bleeding; may increase dose if needed (range: 800 to 1,000 mg/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flebogamma DIF 10%: IV: 1,000 mg/kg once daily for 2 consecutive days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gammagard S/D: IV: 1,000 mg/kg; up to 3 additional doses may be given on alternate days based on patient response and/or platelet count.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gammaked, Gamunex-C: IV: 1,000 mg/kg/day for 2 consecutive days (second dose may be withheld if adequate platelet response in 24 hours) <b>or</b> 400 mg/kg once daily for 5 consecutive days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gammaplex, Octagam 10%, Privigen: IV: 1,000 mg/kg/day for 2 consecutive days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Measles: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GamaSTAN S/D: IM:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immunocompetent: 0.25 <b>mL</b>/kg given within 6 days of exposure</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Postexposure prophylaxis, any nonimmune person: Patients &le;30 kg: 0.5 <b>mL</b>/kg (maximum dose: 15 <b>mL</b>) within 6 days of exposure. If patient &gt;30 kg, patient will have lower titers than what is recommended due to the maximum volume that can be administered (CDC 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gammaked, Gamunex-C, Octagam 5%: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Preexposure prophylaxis in patients with primary humoral immunodeficiency (<b>ONLY</b> if routine dose is &lt;400 mg/kg): &ge;400 mg/kg immediately before expected exposure followed by resumption of prior dosing in 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Postexposure prophylaxis in patients with primary immunodeficiency: 400 mg/kg administered as soon as possible after exposure followed by resumption of prior dosing in 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Postexposure prophylaxis, any nonimmune person: 400 mg/kg within 6 days of exposure (CDC 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hizentra: SubQ infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Preexposure prophylaxis in patients with primary humoral immunodeficiency at risk of measles exposure (eg, during an outbreak; travel to endemic area):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Patients receiving weekly or more frequent dosing:</i> Ensure total weekly dose of &ge;200 mg/kg for 2 consecutive weeks followed by resumption of prior dosing schedule</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Patients receiving biweekly dosing:</i> Administer &ge;400 mg/kg once followed by resumption of prior dosing schedule</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Postexposure prophylaxis in patients with primary humoral immunodeficiency regardless of prior dosing schedule (daily, weekly, or biweekly): 400 mg/kg administered as soon as possible after exposure followed by resumption of prior dosing schedule</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>ACIP recommendations:</i> The Advisory Committee on Immunization Practices (ACIP) recommends postexposure prophylaxis with immune globulin (IG) to any nonimmune person exposed to measles. The following patient groups are at risk for severe measles complications and should receive IG therapy: Infants &lt;12 months of age, pregnant women without evidence of immunity; severely compromised persons (eg, persons with severe primary immunodeficiency; some bone marrow transplant patients; some ALL patients; and some patients with AIDS or HIV infection [refer to guidelines for additional details]). IGIM is recommended for infants &lt;12 months of age. IGIV is recommended for pregnant women and immunocompromised persons. Although prophylaxis may be given to any nonimmune person, priority should be given to those at greatest risk for measles complications and also to persons exposed in settings with intense, prolonged, close contact (eg, households, daycare centers, classrooms). Following IG administration, any nonimmune person should then receive the measles mumps and rubella (MMR) vaccine if the person is &ge;12 months of age at the time of vaccine administration and the vaccine is not otherwise contraindicated. MMR should not be given until 6 months following IGIM or 8 months following IGIV administration. If a person is already receiving IGIV therapy, a dose of 400 mg/kg IV within 3 weeks prior to exposure (or 200 mg/kg SubQ for 2 consecutive weeks prior to exposure if previously on SubQ therapy) should be sufficient to prevent measles infection. IG therapy is not indicated for any person who already received one dose of a measles-containing vaccine at &ge;12 months of age unless they are severely immunocompromised (CDC 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Multifocal motor neuropathy (MMN):</b> Gammagard Liquid: IV: 500 to 2,400 mg/kg/<b>month</b> based upon response</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary humoral immunodeficiency disorders:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>IV infusion dosing: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Bivigam, Gammaplex: IV: 300 to 800 mg/kg every 3 to 4 weeks; dose adjusted based on monitored trough serum IgG concentrations and clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Carimune NF: IV: 400 to 800 mg/kg every 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Flebogamma DIF 5%, Flebogamma DIF 10%, Gammagard Liquid, Gammagard S/D, Gammaked, Gamunex-C, Octagam 5%: IV: 300 to 600 mg/kg every 3 to 4 weeks; dose adjusted based on monitored trough serum IgG concentrations and clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Privigen: IV: 200 to 800 mg/kg every 3 to 4 weeks; dose adjusted based on monitored trough serum IgG concentrations and clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Switching to weekly subcutaneous infusion dosing:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Gammagard Liquid, Gammaked, Gamunex-C: SubQ infusion: Begin 1 week after last IV dose. Use the following equation to calculate initial dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Initial weekly dose (grams) = (1.37 x IGIV dose [grams]) divided by (IV dose interval [weeks])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hizentra: SubQ infusion: For weekly or frequent (up to daily) dosing, begin 1 week after last IV infusion or SubQ infusion. For biweekly (every 2 week) dosing, begin 1 or 2 weeks after last IV infusion or 1 week after the last SubQ weekly infusion. <b>Note:</b> Patient should have received an IV immune globulin routinely for at least 3 months before switching to SubQ. Use the following equation to calculate initial weekly dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Initial weekly dose (grams) = (Previous IGIV dose [grams]) divided by (IV dose interval [eg, 3 or 4 weeks]) then multiply by 1.37. For patients switching to Hizentra from a different SubQ formulation, the previous weekly SubQ dose should be used initially. <b>Note:</b> To convert the dose (in grams) to mL, multiply the calculated dose (in grams) by 5.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note:</b> Provided the total weekly dose is maintained, any dosing interval from daily up to biweekly (every 2 weeks) may be used. Use the following calculations to calculate frequent or biweekly dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Biweekly dosing (grams): Dose = Calculated or previous weekly dose multiplied by 2.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Frequent (2 to 7 times per week) dosing (grams) = divide the calculated or previous weekly dose by the desired number of times per week (eg, for 3 times per week dosing, divide weekly dose by 3).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>SubQ infusion dosing:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Cuvitru: SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Patients switching from another IG SubQ product:</i> SubQ infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>Weekly dosing (grams):</i> Weekly dose is the same as the prior immune globulin subcutaneous weekly dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>Biweekly dosing (grams): </i>Multiply the calculated weekly dose by 2</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>Frequent (2 to 7 times per week) dosing (grams):</i> Divide the calculated weekly dose by the desired number of administration times per week</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Patients switching from IGIV therapy or Hyqvia:</i> SubQ infusion: Begin treatment one week after patient&rsquo;s last immune globulin IV or Hyqvia infusion</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>Initial weekly dosing (grams):</i> Divide the previous immune globulin IV or Hyqvia dose (grams) by the number of weeks between IV doses, then multiply this dose by 1.3 (dose adjustment factor)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>Biweekly dosing (grams): </i>Multiply the calculated weekly dose by 2</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>Frequent (2 to 7 times per week) dosing (grams):</i> Divide the calculated weekly dose by the desired number of times per week</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HyQvia: SubQ: See manufacturer&rsquo;s labeling for initial ramp-up schedule (initiating treatment with a full monthly dose has not been evaluated); dose adjusted based on monitored trough serum IgG concentrations and clinical response after initial ramp-up. <b>Note:</b> For patients previously on another IgG treatment, administer the first dose ~1 week after the last infusion of previous treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Patients naive to IgG therapy or switching from IG SubQ therapy:</i> SubQ infusion: 300 to 600 mg/kg every 3 to 4 weeks, after the initial dose ramp-up</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Patients switching from IGIV therapy:</i> SubQ infusion: Administer the same dose and frequency as the previous IGIV therapy after the initial dose ramp-up. For subsequent dose adjustments, refer to product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rubella:</b> GamaSTAN S/D: IM: Prophylaxis during pregnancy: 0.55 <b>mL</b>/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Varicella:</b> GamaSTAN S/D: IM: Prophylaxis: 0.6 to 1.2 <b>mL</b>/kg (varicella zoster immune globulin preferred) within 72 hours of exposure (Gershon 1978). <b>Note:</b> For patients at risk of thrombosis, administer at the lower end of the recommended dosage range.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Use with caution due to risk of immune globulin-induced renal dysfunction; the rate of infusion and concentration of solution should be minimized. Discontinue if renal function deteriorates during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ infusion: There are no dosage adjustments provided in the manufacturer's labeling; consider lower, more frequent dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> IM, IV, SubQ infusion: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513299\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injectable, Intramuscular [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GamaSTAN S/D: 15% to 18% [150 to 180 mg/mL] (2 mL, 10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hyqvia: 2.5 g/25 mL, 5 g/50 mL, 10 g/100 mL, 20 g/200 mL, 30 g/300 mL [contains albumin human, edetate disodium dihydrate, mouse (murine) and/or hamster protein]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gammagard: 1 g/10 mL (10 mL); 2.5 g/25 mL (25 mL); 5 g/50 mL (50 mL); 10 g/100 mL (100 mL); 20 g/200 mL (200 mL); 30 g/300 mL (300 mL) [latex free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gammaked: 1 g/10 mL (10 mL); 2.5 g/25 mL (25 mL); 5 g/50 mL (50 mL); 10 g/100 mL (100 mL); 20 g/200 mL (200 mL) [latex free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gamunex-C: 1 g/10 mL (10 mL); 2.5 g/25 mL (25 mL); 5 g/50 mL (50 mL); 10 g/100 mL (100 mL); 20 g/200 mL (200 mL); 40 g/400 mL (400 mL) [latex free]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bivigam: 5 g/50 mL (50 mL); 10 g/100 mL (100 mL) [sugar free; contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flebogamma DIF: 0.5 g/10 mL (10 mL); 5 g/50 mL (50 mL); 5 g/100 mL (100 mL); 10 g/100 mL (100 mL); 20 g/200 mL (200 mL); 20 g/400 mL (400 mL); 10 g/200 mL (200 mL); 2.5 g/50 mL (50 mL) [contains polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gammaplex: 5 g/50 mL (50 mL); 5 g/100 mL (100 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gammaplex: 10 g/100 mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gammaplex: 20 g/200 mL (200 mL); 20 g/400 mL (400 mL); 10 g/200 mL (200 mL); 2.5 g/50 mL (50 mL [DSC]) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Octagam: 1 g/20 mL (20 mL); 2 g/20 mL (20 mL); 5 g/50 mL (50 mL); 5 g/100 mL (100 mL); 10 g/100 mL (100 mL); 20 g/200 mL (200 mL); 25 g/500 mL (500 mL); 10 g/200 mL (200 mL); 2.5 g/50 mL (50 mL) [sucrose free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Privigen: 5 g/50 mL (50 mL); 10 g/100 mL (100 mL); 20 g/200 mL (200 mL); 40 g/400 mL (400 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cuvitru: 1 g/5 mL (5 mL); 2 g/10 mL (10 mL); 4 g/20 mL (20 mL); 8 g/40 mL (40 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hizentra: 1 g/5 mL (5 mL); 2 g/10 mL (10 mL); 4 g/20 mL (20 mL); 10 g/50 mL (50 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carimune NF: 3 g (1 ea [DSC]); 6 g (1 ea); 12 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gammagard S/D: 5 g (1 ea [DSC]); 10 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gammagard S/D Less IgA: 5 g (1 ea); 10 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513236\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26116456\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">see &quot;Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carimune NF may contain a significant amount of sodium and also contains sucrose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gammagard S/D may contain a significant amount of sodium and also contains glucose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Octagam contains maltose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyqvia Kit is supplied with a Hyaluronidase (Human Recombinant) component intended for injection prior to Immune Globulin administration to improve dispersion and absorption of the Immune Globulin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13307649\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;\">\n      <b>Note:</b> If plasmapheresis employed for treatment of condition, administer immune globulin <b>after</b> completion of plasmapheresis session.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse over 2 to 24 hours with initial infusion administered slowly and titrated as tolerated; administer in separate infusion line from other medications; if using primary line, flush with NS or D5W (product specific; consult product prescribing information) prior to administration. Decrease dose, rate, and/or concentration of infusion in patients who may be at risk of renal failure. Decreasing the rate or stopping the infusion may help relieve some adverse effects (flushing, changes in pulse rate, changes in blood pressure). Epinephrine should be available during administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">For initial treatment, a lower concentration and/or a slower rate of infusion should be used. Initial rate of administration and titration is specific to each IVIG product. Refrigerated products should be warmed to room temperature prior to infusion. Some products require filtration; refer to individual product labeling. Antecubital veins should be used, especially with concentrations &ge;10% to prevent injection site discomfort.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bivigam 10%: Primary humoral immunodeficiency: Initial rate: 0.5 mg/kg/minute (0.3 <b>mL</b>/kg/<b>hour</b>) for 10 minutes; if tolerated, increase every 20 minutes by 0.8 mg/kg/minute (0.48 <b>mL</b>/kg/<b>hour</b>) up to 6 mg/kg/minute (3.6 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Carimune NF: Initial rate: 0.5 mg/kg/minute for 30 minutes; if tolerated increase to 1 mg/kg/minute, if tolerated after 30 minutes, may increase gradually up to 3 mg/kg/minute; rate in mL/kg/hour varies based on concentration; refer to product labeling</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flebogamma DIF 5%: Primary humoral immunodeficiency: Initial rate: 0.5 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>) for the first 30 minutes; if tolerated increase slowly up to 5 mg/kg/minute (6 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flebogamma DIF 10%: Primary humoral immunodeficiency or immune thrombocytopenia: Initial rate: 1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>) for first 30 minutes; if tolerated increase slowly up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gammagard Liquid 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Multifocal motor neuropathy (MMN): Initial rate: 0.8 mg/kg/minute (0.5 <b>mL</b>/kg/<b>hour)</b>; if tolerated increase gradually up to 9 mg/kg/minute (5.4 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Primary humoral immunodeficiency: Initial rate: 0.8 mg/kg/minute (0.5 <b>mL</b>/kg/<b>hour</b>) for 30 minutes; if tolerated increase every 30 minutes up to 8 mg/kg/minute (5 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gammagard S/D: 5% solution: Initial rate: 0.5 <b>mL</b>/kg/<b>hour</b>; if tolerated may increase to a maximum rate of 4 <b>mL</b>/kg/<b>hour</b>. If 5% solution is tolerated at maximum rate, may administer 10% solution with an initial rate of 0.5 <b>mL</b>/kg/<b>hour</b>; if tolerated may increase to a maximum rate of 8 <b>mL</b>/kg/<b>hour</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gammaked 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CIDP: Initial rate: 2 mg/kg/minute (1.2 <b>mL</b>/kg/<b>hour</b>) for 30 minutes; if tolerated increase gradually up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Primary humoral immunodeficiency or ITP: Initial rate: 1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>) for 30 minutes; if tolerated increase gradually up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gammaplex 5%: Primary humoral immunodeficiency or ITP: Initial rate: 0.5 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>) for 15 minutes; if tolerated increase every 15 minutes up to 4 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gammaplex 10%: Primary humoral immunodeficiency or ITP: Initial rate: 0.5 mg/kg/minute (0.3 <b>mL</b>/kg/<b>hour</b>) for 15 minutes; if tolerated increase every 15 minutes up to 4 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gamunex-C 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CIDP: Initial rate: 2 mg/kg/minute (1.2 <b>mL</b>/kg/<b>hour</b>) for 30 minutes; if tolerated increase gradually up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Primary humoral immunodeficiency or ITP: Initial rate: 1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>) for 30 minutes; if tolerated increase gradually up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Octagam 5%: Primary humoral immunodeficiency: Initial rate: 0.5 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>) for 30 minutes; if tolerated double the infusion rate every 30 minutes up to a maximum rate of &lt;3.33 mg/kg/minute (4.2 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Octagam 10%: ITP: Initial rate: 1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>) for 30 minutes; if tolerated double the infusion rate every 30 minutes up to a maximum rate of 12 mg/kg/minute (7.2 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Privigen 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ITP: Initial rate: 0.5 mg/kg/minute (0.3 <b>mL</b>/kg/<b>hour</b>); if tolerated increase gradually up to 4 mg/kg/minute (2.4 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Primary humoral immunodeficiency: Initial rate: 0.5 mg/kg/minute (0.3 <b>mL</b>/kg/<b>hour</b>); if tolerated increase gradually up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CIDP: Initial rate: 0.5 mg/kg/minute (0.3 <b>mL</b>/kg/<b>hour</b>); if tolerated increase gradually up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Administer IM in the anterolateral aspects of the upper thigh or deltoid muscle of the upper arm. Avoid gluteal region due to risk of injury to sciatic nerve. Divide doses &gt;10 mL (adult) and inject in multiple sites; in pediatric patients, consider splitting doses &lt;10 mL based on patient size.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ infusion: Initial dose should be administered in a healthcare setting capable of providing monitoring and treatment in the event of hypersensitivity. Using aseptic technique, follow the infusion device manufacturer&rsquo;s instructions for filling the reservoir and preparing the pump. Remove air from administration set and needle by priming. For products excluding HyQvia, appropriate injection sites include the abdomen, thigh, upper arm, lateral hip, and/or lower back; dose may be infused into multiple sites (spaced &ge;2 inches apart) simultaneously. HyQvia may be injected into the middle to upper abdomen or thigh (avoid bony prominences, or areas that are scarred, inflamed, or infected). If two sites are used simultaneously for HyQvia, the two infusion sites should be on opposite sides of the body. After administration sites are clean and dry, insert subcutaneous needle and prime administration set. Attach sterile needle to administration set, gently pull back on the syringe to assure a blood vessel has not been inadvertently accessed; if blood is present, remove and discard needle and tubing; repeat process using a new needle and tubing and different injection site. Repeat for each injection site; deliver the dose following instructions for the infusion device. Rotate the site(s) between successive infusions. Treatment may be transitioned to the home/home care setting in the absence of adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cuvitru: <b>Note: </b>It is recommended that infusion be complete within 2 hours of preparation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Injection sites: &le;4 simultaneous injection sites (spaced 4 inches apart or more)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum infusion rate<b>: </b>10 to 20 mL/hour per injection site (first 2 infusions); may be increased to 60 mL/hour per injection site (as tolerated) for subsequent infusions</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum infusion volume:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients &lt;40 kg: 20 mL per injection site (first 2 infusions); may increase to 60 mL per site for subsequent infusions</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients &ge;40 kg: 60 mL per injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gammagard Liquid:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Injection sites: &le;8 simultaneous injection sites</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Recommended infusion rate:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;40 kg (&lt;88 lbs): Initial infusion: 15 mL/hour per injection site; subsequent infusions: 15 to 20 mL/hour per injection site; maximum: 160 mL/hour for all simultaneous sites combined</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;40 kg (&ge;88 lbs): Initial infusion: 20 mL/hour per injection site; subsequent infusions: 20 to 30 mL/hour per injection site; maximum: 240 mL/hour for all simultaneous sites combined</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum infusion volume:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;40 kg (&lt;88 lbs): 20 mL per injection site</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;40 kg (&ge;88 lbs): 30 mL per injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gammaked, Gamunex-C:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Injection sites: <b>Note: </b>Space injection site &ge;2 inches apart.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents: &le;6 simultaneous injection sites</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adults: &le;8 simultaneous injection sites</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Recommended infusion rate:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;25 kg: 10 mL/hour per infusion site</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;25 kg: Initial: 15 mL/hour per infusion site; may increase up to 20 mL/hour per infusion site</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adults: 20 mL/hour per injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hizentra:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Injection sites: &le;4 simultaneous injection sites <b>or</b> &le;12 sites consecutively per infusion</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum infusion rate: First infusion: 15 mL/hour per injection site; subsequent infusions: 25 mL/hour per injection site</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum infusion volume: First 4 infusions: 15 mL per injection site; subsequent infusions: 20 mL per injection site; maximum: 25 mL per site as tolerated</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HyQvia: Administer components of HyQvia (immune globulin and hyaluronidase) sequentially, beginning with the hyaluronidase; do not use either component alone. Infusion pump capable of infusing rates up to 300 mL/hour/site required; must also have the ability to titrate the flow rate. Use a 24-gauge subcutaneous needle set labeled for high flow rates. Initiate the infusion of the full dose of the immune globulin through the same subcutaneous needle set within ~10 minutes of hyaluronidase infusion. For each full or partial vial of immune globulin used, administer the entire contents of the hyaluronidase vial. A second site can be used based on tolerability and total volume; if a second site is used, administer half of total volume of the hyaluronidase in each site. Flush the infusion line with NS or D5W if required.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Volume per site:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;40 kg: &le;300 mL per injection site</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;40 kg: &le;600 mL per injection site</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infusion rate:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immune globulin:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">First 2 infusions:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&lt;40 kg: 5 mL/hour for 5 to 15 minutes; 10 mL/hour for 5 to 15 minutes; 20 mL/hour for 5 to 15 minutes; 40 mL/hour for 5 to 15 minutes; then 80 mL/hour for remainder of infusion</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ge;40 kg: 10 mL/hour for 5 to 15 minutes; 30 mL/hour for 5 to 15 minutes; 60 mL/hour for 5 to 15 minutes; 120 mL/hour for 5 to 15 minutes; then 240 mL/hour for remainder of infusion</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Next 2 or 3 infusions:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&lt;40 kg: 10 mL/hour for 5 to 15 minutes; 20 mL/hour for 5 to 15 minutes; 40 mL/hour for 5 to 15 minutes; 80 mL/hour for 5 to 15 minutes; then 160 mL/hour for remainder of infusion</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ge;40 kg: 10 mL/hour for 5 to 15 minutes; 30 mL/hour for 5 to 15 minutes; 120 mL/hour for 5 to 15 minutes; 240 mL/hour for 5 to 15 minutes; then 300 mL/hour for remainder of infusion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513261\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Stability is dependent upon the manufacturer and brand. Do not freeze (do not use if previously frozen). Do not shake. Do not heat (do not use if previously heated).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Bivigam: Store under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Dilution is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carimune NF: Prior to reconstitution, store at or below 30&deg;C (86&deg;F). Do not freeze. Following reconstitution in a sterile laminar air flow environment, store under refrigeration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cuvitru: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for up to 36 months or at room temperature (&le;25&deg;C [&le;77&deg;F]) for up to 12 months; do not return vial to refrigerator after it has been stored at room temperature. Do not freeze. Keep in original carton to protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flebogamma DIF: Store at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F). Keep in original carton to protect from light. Do not freeze or use if solution has been frozen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GamaSTAN S/D: Store under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). The following stability information has also been reported for GamaSTAN S/D: May be exposed to room temperature for a cumulative 7 days (Cohen 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gammagard Liquid: Prior to use, may store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for up to 36 months or at &le; 25&deg;C (&le;77&deg;F) for up to 24 months. Do not freeze.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gammagard S/D: Store at &le;25&deg;C (&le;77&deg;F) for up to 24 months. May store diluted solution under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for up to 24 hours if originally prepared in a sterile laminar air flow environment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gammaked: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); may be stored at &le;25&deg;C (&le;77&deg;F) for up to 6 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gammaplex: Store at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F). Keep in original carton to protect from light. Do not freeze or use if solution has been frozen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gamunex-C: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); may be stored at &le;25&deg;C (&le;77&deg;F) for up to 6 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hizentra: Store at &le;25&deg;C (&le;77&deg;F). Keep in original carton to protect from light. Do not freeze or use if solution has been frozen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HyQvia: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for up to 36 months; may store at &le;25&deg;C (&le;77&deg;F) for up to 3 months during the first 24 months from the date of manufacture (after 3 months at room temperature, discard); do not return vial to refrigerator after it has been stored at room temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Octagam 5%: Store at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Octagam 10%: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for 24 months from the date of manufacture; within these first 12 months, may store up to 9 months at &le;25&deg;C (77&deg;F); after storage at &le;25&deg;C (77&deg;F), the product must be used or discarded.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panzyga [Canadian product]: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for 24 months from the date of manufacture; within this time, may store up to 6 months at &le;25&deg;C (&le;77&deg;F); after storage at &le;25&deg;C (&le;77&deg;F) the product must be used or discarded. Do not freeze. Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Privigen: Store at &le;25&deg;C (&le;77&deg;F). Do not freeze or use if solution has been frozen. Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13307641\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of primary humoral immunodeficiency syndromes (may include but not limited to: Congenital agammaglobulinemia, severe combined immunodeficiency syndromes [SCIDS], common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome); acute and chronic immune thrombocytopenia (ITP); chronic inflammatory demyelinating polyneuropathy (CIDP); and multifocal motor neuropathy. Prevention of coronary artery aneurysms associated with Kawasaki syndrome (in combination with aspirin).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adjunctive treatment of bacterial infection in patients with hypogammaglobulinemia and/or recurrent bacterial infections with B-cell chronic lymphocytic leukemia (CLL); and serious infection in immunoglobulin deficiency (select agammaglobulinemias).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">To provide passive immunity for prophylaxis in the following susceptible individuals: Hepatitis A (pre-exposure and postexposure [within 14 days and prior to manifestation of disease]); measles (postexposure [within 6 days] in an unvaccinated or nonimmune person); rubella (postexposure during early pregnancy); and varicella zoster (immunosuppressed patients when varicella zoster immune globulin is unavailable).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">See table for product specific indications, FDA approved age ranges, and routes of administration.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Product</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Indication</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">FDA Approval Ages</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Route(s)</p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Bivigam</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Primary immunodeficiency (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;6 years and adults</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Intravenous</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Carimune NF</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Primary immunodeficiency (treatment)</p></td>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Pediatric patients (age not specified) and adults</p></td>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Intravenous</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Acute and chronic ITP (treatment)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Cuvitru</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Primary immunodeficiency (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;2 years and adults</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Subcutaneous</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Flebogamma 5% DIF</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Primary immunodeficiency (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;2 years and adults</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Intravenous</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Flebogamma 10% DIF</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Primary immunodeficiency (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Adults</p></td>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Intravenous</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Chronic ITP (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;2 years and adults</p></td></tr>\n        <tr>\n          <td rowspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">GamaSTAN S/D</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Passive immunity - Hepatitis A</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Adults</p></td>\n          <td rowspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">Intramuscular</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Passive immunity - Measles</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Pediatric patients (age not specified) and adults</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Passive immunity - Rubella</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Adults</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Passive immunity - Varicella</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Adults</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Gammagard Liquid</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Primary immunodeficiency (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;2 years and adults</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Intravenous, Subcutaneous</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Multifocal motor neuropathy (MMN)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Adults</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Intravenous</p></td></tr>\n        <tr>\n          <td rowspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">Gammagard S/D</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Primary immunodeficiency (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;2 years and adults</p></td>\n          <td rowspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">Intravenous</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">B-cell chronic lymphocytic leukemia (CLL)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Adults</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Chronic ITP (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Adults</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Kawasaki syndrome</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Pediatric patients (age not specified)</p></td></tr>\n        <tr>\n          <td rowspan=\"3\" align=\"center\">\n            <p style=\"text-indent:0em;\">Gammaked</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Primary immunodeficiency (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge; 2 years and adults</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Intravenous, Subcutaneous</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Acute and chronic ITP (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Pediatric patients (age not specified) and adults</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Intravenous</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Chronic inflammatory demyelinating polyneuropathy (CIDP)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Adults</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Intravenous</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Gammaplex 5%</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Primary immunodeficiency (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;2 years and adults</p></td>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Intravenous</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Chronic ITP (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Adults</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Gammaplex 10%</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Primary immunodeficiency (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Adults</p></td>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Intravenous</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Chronic ITP (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Adults</p></td></tr>\n        <tr>\n          <td rowspan=\"3\" align=\"center\">\n            <p style=\"text-indent:0em;\">Gamunex-C</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Primary immunodeficiency (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;2 years and adults</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Intravenous, Subcutaneous</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Acute and chronic ITP (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Pediatric patients (age not specified) and adults</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Intravenous</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Chronic inflammatory demyelinating polyneuropathy (CIDP)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Adults</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Intravenous</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hizentra</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Primary immunodeficiency (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;2 years and adults</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Subcutaneous</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">HyQvia</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Primary immunodeficiency (treatment), in conjunction with a recombinant human hyaluronidase</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Adults</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Subcutaneous</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Octagam 5%</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Primary immunodeficiency (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6 to 16 years and adults</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Intravenous</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Octagam 10%</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Chronic ITP (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Adults</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Intravenous</p></td></tr>\n        <tr>\n          <td rowspan=\"3\" align=\"center\">\n            <p style=\"text-indent:0em;\">Privigen</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Primary immunodeficiency (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;3 years and adults</p></td>\n          <td rowspan=\"3\" align=\"center\">\n            <p style=\"text-indent:0em;\">Intravenous</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Chronic ITP (treatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;15 years and adults</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Chronic inflammatory demyelinating polyneuropathy (CIDP)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Adults</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:0em;margin-top:2em;\">Has also been used for acute disseminated encephalomyelitis (ADEM), acute myocarditis, chronic <i>Clostridium difficile</i> colitis, Guillain-Barr&eacute; syndrome, hematopoietic stem cell transplantation with hypogammaglobulinemia, isoimmune hemolytic disease (Rh-incompatibility), multiple sclerosis, myasthenia gravis, neonatal sepsis, pediatric HIV infection and associated thrombocytopenia, refractory dermatomyositis, Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), and refractory polymyositis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513231\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gamimune N may be confused with CytoGam</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immune globulin (intravenous) may be confused with hepatitis B immune globulin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Privigen (immune globulin) may be confused with Albuminar-25 (albumin) due to similar packaging </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513251\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects are reported as class effects rather than for specific products. Adverse effects occur with intravenous administration unless otherwise specified.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac arrest, chest discomfort, chest pain, decreased diastolic blood pressure (more common in children and adolescents), decreased heart rate, facial flushing, flushing, heart murmur, hypertension, hypotension (more common in children and adolescents), peripheral edema, tachycardia (more common in children and adolescents), thrombosis (including vena cava)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, dizziness, drowsiness, fatigue, fibromyalgia syndrome (exacerbation), headache, insomnia, lethargy, malaise, migraine, pain, rigors, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Cellulitis, ecchymosis, eczema (may be transient), erythema, hyperhidrosis, injection site pruritus, skin rash, urticaria (may be transient), xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Dehydration, increased lactate dehydrogenase, ketonuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distress, abdominal pain, diarrhea, dyspepsia, gastritis, gastroenteritis, nausea, pseudomembranous colitis, sore throat, stomach discomfort, upper abdominal pain, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Cystitis, dysuria, urinary tract infection, vulvovaginal candidiasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, bruise, decreased hematocrit, hematoma, hemorrhage, petechiae, positive direct Coombs test, purpura, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Decreased serum alkaline phosphatase (subcutaneous), hyperbilirubinemia, increased serum alkaline phosphatase (subcutaneous; mild and transient), increased serum ALT (all elevations were transient and generally mild), increased serum AST (intravenous/subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Antibody development (subcutaneous; non-neutralizing antibodies to recombinant human hyaluronidase)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Coxsackievirus, fungal infection, influenza</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Erythema at injection site, infusion site reaction (more common in subcutaneous), local inflammation (at infusion site), local swelling (at injection/infusion site), local pain (intramuscular/subcutaneous), localized tenderness (intramuscular), pain at injection site (injection/infusion site)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular and skeletal: Arthralgia, back pain, joint effusion, joint swelling, leg cramps, limb pain (intravenous/subcutaneous), muscle cramps, muscle spasm, myalgia, myasthenia, neck pain, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, conjunctivitis, eye discharge, eye irritation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otalgia (subcutaneous), otitis media</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen, increased serum creatinine, nephrolithiasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma (including exacerbation), bronchitis, cough, dyspnea, epistaxis, exacerbation of asthma, flu-like symptoms, nasal congestion, nasal mucosa swelling, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngolaryngeal pain, pneumonia, post nasal drip, rhinitis, rhinorrhea, sinus congestion, sinusitis, throat irritation, tonsil disease (children), upper respiratory tract infection, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Accidental injury, fever (subcutaneous), positive culture</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute renal failure, acute respiratory distress, agitation, allergic dermatitis, alopecia, altered blood pressure, anaphylactic shock, anaphylactoid reaction, anaphylaxis, angioedema, anorexia, anxiety, apnea, arterial thrombosis, aseptic meningitis, bradycardia, bronchospasm, bullous dermatitis, burning sensation, cerebrovascular accident, chest tightness, circulatory shock, coma, cyanosis, deep vein thrombosis, dermatitis, disseminated intravascular coagulation (intravenous, subcutaneous, intramuscular; FDA Safety Communication, November 13, 2012), edema, epidermolysis, erythema multiforme, erythematous rash, exacerbation of autoimmune pure red cell aplasia, eye pain, facial edema, hematuria, hemoglobinuria, hemolysis (may be mild), hemolytic anemia (may be delayed), hepatic insufficiency, hepatitis (non-infectious), hyperventilation, hypervolemia, hypoxemia, jaundice, laryngospasm, leukopenia, loss of consciousness, lymphadenopathy, muscle rigidity, musculoskeletal pain, myocardial infarction, osmotic nephrosis, oxygen saturation decreased, pallor, palpitations, pancytopenia, paresthesia, peripheral vascular insufficiency, pharyngeal edema, phlebitis, photophobia, proximal tubular nephropathy, pulmonary edema, pulmonary embolism, renal failure, renal insufficiency, renal tubular necrosis, respiratory distress, respiratory failure, restlessness, retinal thrombosis, seizure, skin ulceration at injection site (infusion site), Stevens-Johnson syndrome, syncope, thromboembolism, thrombophlebitis, transfusion-related acute lung injury, transient ischemic attacks, tremor, urine discoloration, vena cava thrombosis, visual impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513246\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to immune globulin or any component of the formulation; IgA deficiency (with anti-IgA antibodies and history of hypersensitivity [excluding Gammagard S/D]); hyperprolinemia (Hizentra, Privigen); isolated IgA deficiency (GamaSTAN S/D); severe thrombocytopenia or coagulation disorders where IM injections are contraindicated (GamaSTAN S/D); hypersensitivity to corn (Octagam); hereditary intolerance to fructose (excluding Flebogamma); infants/neonates for whom sucrose or fructose tolerance has not been established (Gammaplex); hypersensitivity to hyaluronidase, human albumin, or any component of the hyaluronidase formulation (HyQvia)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for immune globulins is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513247\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur (some severe); patients with known antibodies to IgA are at greater risk; a severe fall in blood pressure may rarely occur with anaphylactic reaction; discontinue therapy and institute immediate treatment (including epinephrine 1 mg/mL) should be available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aseptic meningitis: Aseptic meningitis syndrome (AMS) has been reported with immune globulin administration; may occur with high doses (&ge;1 g/kg) and/or rapid infusion. Syndrome usually appears within several hours to 2 days following treatment; usually resolves within several days after product is discontinued. Female patients or patients with a migraine history may be at higher risk for AMS.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematoma: Increased risk of hematoma formation when administered subcutaneously for the treatment of ITP.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemolysis: Intravenous immune globulin has been associated with antiglobulin hemolysis (acute or delayed). Cases of hemolysis-related renal impairment/failure or disseminated intravascular coagulation (DIC) have been reported. Risk factors associated with hemolysis include high doses (&ge;2 g/kg) given either as a single administration or divided over several days, underlying associated inflammatory conditions, and non-O blood type (FDA 2012). An underlying inflammatory state (eg, elevated C-reactive protein or erythrocyte sedimentation rate) may also increase the risk. Closely monitor patients for signs of hemolytic anemia, particularly in patients with pre-existing anemia and/or cardiovascular or pulmonary compromise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hereditary fructose intolerance: Immune globulin may contain sorbitol. The presence of sorbitol presents a risk to those with hereditary fructose intolerance (HFI). The incidence of HFI is estimated at 1 in 20,000 births and is usually diagnosed at the time of weaning when fructose or sucrose is introduced into the diet. Clinical symptoms include recurrent vomiting, abdominal pain, and hypoglycemia. Immune globulin must not be administered to patients with HFI.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperproteinemia: Hyperproteinemia, increased serum viscosity, and hyponatremia may occur; distinguish hyponatremia from pseudohyponatremia to prevent volume depletion, a further increase in serum viscosity and a higher risk of thrombotic events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension urgency: Elevations of blood pressure (systolic &ge;180 mm Hg and/or diastolic &ge;120 mm Hg) have been observed during and/or shortly following infusion of Privigen which resolved with either observation or changes in oral anti-hypertensive therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Patients should be monitored for adverse events during and after the infusion. Stop administration with signs of infusion reaction (fever, chills, nausea, vomiting, and rarely shock). Risk may be increased with initial treatment, when switching brands of immune globulin, and with treatment interruptions of &gt;8 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary edema: Monitor for transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with immune globulin use. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever in the presence of normal left ventricular function. Usually occurs within 1 to 6 hours after infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: <b>[US Boxed Warning]: IV administration only: Acute renal dysfunction (increased serum creatinine, oliguria, acute renal failure, osmotic nephrosis) can rarely occur and has been associated with fatalities; usually within 7 days of use (more likely with products stabilized with sucrose). Use with caution in the elderly, patients with renal disease, diabetes mellitus, overweight, hypovolemia, volume depletion, sepsis, paraproteinemia, and nephrotoxic medications due to risk of renal dysfunction.</b> In patients at risk of renal dysfunction, ensure adequate hydration prior to administration; the dose rate of infusion and concentration of solution should be minimized. Assess renal function prior to treatment and periodically thereafter. Discontinue if renal function deteriorates.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events:<b> [US Boxed Warning]: Thrombosis may occur with immune globulin products even in the absence of risk factors for thrombosis. For patients at risk of thrombosis (eg, advanced age, history of atherosclerosis, impaired cardiac output, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors), administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity such as those with cryoglobulins, fasting chylomicronemia/severe hypertriglyceridemia, or monoclonal gammopathies.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid overload: High-dose regimens (1 g/kg for 1 to 2 days) are not recommended for individuals with fluid overload or where fluid volume may be of concern.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypovolemia: Patients should not be volume depleted prior to initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IgA deficiency: Increased risk of hypersensitivity, especially in patients with anti-IgA antibodies; use is contraindicated in patients with IgA deficiency (with antibodies against IgA and history of hypersensitivity) or isolated IgA deficiency (GamaSTAN S/D).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; ITP, chronic: Consider risk versus benefit for high-dose regimen in patients with increased risk of thrombosis, hemolysis, acute kidney injury, or volume overload.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution; ensure adequate hydration prior to administration; the rate of infusion and concentration of solution should be minimized.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may be at increased risk for renal dysfunction/failure and thromboembolic events.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents (eg, viruses, the variant Creutzfeldt Jakob disease [vCJD] agent and, theoretically, the Creutzfeldt Jakob disease [CJD] agent) which could transmit disease, including unknown or emerging viruses and other pathogens. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: Packaging of some products may contain natural latex/natural rubber.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; L-proline: Hizentra and Privigen contain the stabilizer L-proline and are contraindicated in patients with hyperprolinemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Maltose: Some products may contain maltose, which may result in falsely elevated blood glucose readings. Maltose-containing products may be contraindicated with patients with corn allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC, 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin testing: Skin testing should not be performed with GamaSTAN S/D as local irritation can occur and be misinterpreted as a positive reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sodium: Some products may contain sodium.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sorbitol: Some products may contain sorbitol; do not use immune globulin in patients with hereditary fructose intolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Subcutaneous administration: Some clinicians may administer intravenous immune globulin products as a subcutaneous infusion based on patient tolerability and clinical judgment. SubQ infusion should begin 1 week after the last IV dose; dose should be individualized based on clinical response and serum IgG trough concentrations. Consider premedicating with acetaminophen and diphenhydramine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sucrose: Some products may contain sucrose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Patients should be adequately hydrated prior to therapy. Do not infuse into or around an infected area due to the risk of spreading a localized infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Privigen maintenance therapy in chronic inflammatory demyelinating polyneuropathy (CIDP) has not been studied for periods longer than 6 months; after responding during an initial treatment period, not all patients require indefinite maintenance therapy in order to remain free of CDIP symptoms; individualize the duration of any treatment beyond 6 months based upon patient's response and need for continued therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccinations: Response to live vaccinations may be impaired.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299513\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513254\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=83878&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May enhance the thrombogenic effect of Immune Globulin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Consult full interaction monograph for dose interval recommendations.  This interaction does not apply to oral Ty21a typhoid vaccine or others listed as exceptions.<b> Exceptions: </b>Influenza Virus Vaccine (Live/Attenuated); Rotavirus Vaccine; Yellow Fever Vaccine; Zoster Vaccine (Live/Attenuated).<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513243\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513244\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Immune globulins cross the placenta in increased amounts after 30 weeks gestation. Intravenous immune globulin has been recommended for use in fetal-neonatal alloimmune thrombocytopenia and pregnancy-associated ITP (ACOG 2016; Anderson, 2007; Neunert 2011); use is appropriate for ITP in cases refractory to corticosteroids, when side effects to corticosteroids are significant, or when a rapid increase in platelets is needed (ACOG 2016). Intravenous immune globulin is recommended to prevent measles in nonimmune women exposed during pregnancy (CDC 2013). May also be used in postexposure prophylaxis for rubella to reduce the risk of infection and fetal damage in exposed pregnant women who will not consider therapeutic abortion (per GamaSTAN S/D product labeling; use for postexposure rubella prophylaxis is not currently recommended [CDC 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>HyQvia:</i></b> Women who become pregnant during treatment are encouraged to enroll in the HyQvia Pregnancy Registry (1-866-424-6724).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13307650\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function (prior to initial infusion and at appropriate intervals), urine output, IgG concentrations, hemoglobin and hematocrit, platelets (in patients with ITP); infusion- or injection-related adverse reactions, anaphylaxis, signs and symptoms of hemolysis; blood viscosity (in patients at risk for hyperviscosity); presence of antineutrophil antibodies (if TRALI is suspected); volume status; neurologic symptoms (if aseptic meningitis syndrome suspected); pulmonary adverse reactions; clinical response (as defined by disease state)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">For patients at high risk of hemolysis (dose &ge;2000 mg/kg, given as a single dose or divided over several days, and non-O blood type): Hemoglobin or hematocrit prior to and 36 to 96 hours postinfusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ infusion: Monitor IgG trough levels every 2 to 3 months before/after conversion from IV; subcutaneous infusions provide more constant IgG levels than usual IV immune globulin treatments</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513265\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Replacement therapy for primary and secondary immunodeficiencies, and IgG antibodies against bacteria, viral, parasitic and mycoplasma antigens; interference with F<sub>c</sub> receptors on the cells of the reticuloendothelial system for autoimmune cytopenias and ITP; provides passive immunity by increasing the antibody titer and antigen-antibody reaction potential </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513267\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: IV: Provides immediate antibody levels</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immune thrombocytopenia: Initial response: 1 to 3 days; Peak response: 2 to 7 days (Neunert 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: IM, IV: Immune effect: 3 to 4 weeks (variable)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 0.05 to 0.13 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intravascular portion (primarily): Healthy subjects: 41% to 57%; Patients with congenital humoral immunodeficiencies: ~70%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IM: ~23 days; SubQ: ~59 days (HyQvia); IV: IgG (variable among patients): Healthy subjects: 14 to 24 days; Patients with congenital humoral immunodeficiencies: 26 to 40 days; hypermetabolism associated with fever and infection have coincided with a shortened half-life</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Plasma: SubQ: Cuvitru: ~4.4 days; Gammagard Liquid: 2.9 days; Hizentra: 2.9 days; HyQvia: ~5 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum: IM: ~48 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13307652\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: When administering immune globulin for hepatitis A prophylaxis, use should be considered for the following close contacts of persons with confirmed hepatitis A: Unvaccinated household and sexual contacts, persons who have shared illicit drugs, regular babysitters, staff and attendees of child care centers, food handlers within the same establishment (CDC, 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DIF: Dual inactivation plus nanofiltration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NF: Nanofiltered</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">S/D: Solvent detergent treated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Octagam contains sodium 30 mmol/L.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IgA content:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bivigam: &le;200 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Carimune NF: Manufacturer's labeling: Trace amounts; others have reported 1000-2000 mcg/mL in a 6% solution (Siegel, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cuvitru: 80 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flebogamma 5% DIF: &lt;50 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flebogamma 10% DIF: &lt;32 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gammagard Liquid: 37 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gammagard S/D 5% solution: &lt;1 mcg/mL or &lt;2.2 mcg/mL (product dependent) (see <b>Note</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gammaked: 46 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gammaplex 5%: &lt;10 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gammaplex 10%: &lt;20 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gamunex-C: 46 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hizentra: &le;50 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HyQvia: &le;37 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Octagam 5%: &le;200 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Octagam 10%: 106 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Privigen: &le;25 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Manufacturer has discontinued Gammagard S/D 5% solution; however, the lower IgA product will remain available by special request for patients with known reaction to IgA or IgA deficiency with antibodies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322887\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Hyqvia Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 g/25 mL (26.25 mL): $566.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 gm/50 mL (52.5 mL): $1,132.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/100 mL (105 mL): $2,264.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/200 mL (210 mL): $4,528.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 g/300 mL (315 mL): $6,793.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Bivigam Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 gm/50 mL (50 mL): $798.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/100 mL (100 mL): $1,596.59</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cuvitru Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/5 mL (5 mL): $205.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g/10 mL (10 mL): $411.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g/20 mL (20 mL): $822.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 g/40mL (40 mL): $1,645.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Flebogamma DIF Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 g/10 mL (10 mL): $54.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 gm/50 mL (50 mL): $274.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 g/100 mL (100 mL): $548.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 gm/50 mL (50 mL): $548.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/100 mL (100 mL): $1,096.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/200 mL (200 mL): $1,096.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/200 mL (200 mL): $2,192.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/400 mL (400 mL): $2,192.18</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Gammagard Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/10 mL (10 mL): $159.89</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 g/25 mL (25 mL): $399.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 gm/50 mL (50 mL): $799.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/100 mL (100 mL): $1,598.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/200 mL (200 mL): $3,197.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 g/300 mL (300 mL): $4,796.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Gammaked Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/10 mL (10 mL): $152.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 g/25 mL (25 mL): $380.14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 gm/50 mL (50 mL): $760.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/100 mL (100 mL): $1,520.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/200 mL (200 mL): $3,041.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Gammaplex Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 g/100 mL (100 mL): $914.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 gm/50 mL (50 mL): $943.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/100 mL (100 mL): $1,887.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/200 mL (200 mL): $1,829.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/200 mL (200 mL): $3,775.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/400 mL (400 mL): $3,658.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Gamunex-C Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/10 mL (10 mL): $131.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 g/25 mL (25 mL): $328.87</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 gm/50 mL (50 mL): $657.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/100 mL (100 mL): $1,315.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/200 mL (200 mL): $2,631.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 g/400 mL (400 mL): $5,261.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Hizentra Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/5 mL (5 mL): $201.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g/10 mL (10 mL): $403.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g/20 mL (20 mL): $806.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 gm/50 mL (50 mL): $2,016.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Octagam Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/20 mL (20 mL): $166.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g/20 mL (20 mL): $332.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 gm/50 mL (50 mL): $415.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 g/100 mL (100 mL): $830.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 gm/50 mL (50 mL): $830.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/100 mL (100 mL): $1,661.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/200 mL (200 mL): $1,661.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/200 mL (200 mL): $3,322.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 g/500 mL (500 mL): $4,152.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Privigen Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 gm/50 mL (50 mL): $816.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/100 mL (100 mL): $1,632.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/200 mL (200 mL): $3,264.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 g/400 mL (400 mL): $6,528.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Carimune NF Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 g (1): $691.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 g (1): $1,382.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Gammagard S/D Less IgA Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 g (1): $1,012.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (1): $2,024.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059490\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Allerglobuline (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Aragam (GB);</li>\n      <li>Aunativ (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Beriglobin (AE, AT, BH, CH, CY, DE, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SE, SY, YE);</li>\n      <li>Beriglobin P (AR, TW);</li>\n      <li>Beriglobina (BR, ES);</li>\n      <li>Beriglobina P (CL);</li>\n      <li>Endobulin (CZ, FI);</li>\n      <li>Flebogamma (HK, IL, MY, SG, TH);</li>\n      <li>Gamastan Immune Globulin (IL);</li>\n      <li>Gamimune (KW, QA);</li>\n      <li>Gamma 16 (IL);</li>\n      <li>Gamma I.V. (IN, PH);</li>\n      <li>Gammagard (BG, DK, ES, FR, GB, HN, IT, NL, PL, SE);</li>\n      <li>Gammagard S/D (HK, IL, SA);</li>\n      <li>Gammanorm (AE, FR, GB);</li>\n      <li>Gammaplex (GB);</li>\n      <li>Gammonativ (AE, BH, CY, DE, DK, EG, IQ, IR, JO, KW, LB, LY, NO, OM, QA, SA, SE, SY, YE);</li>\n      <li>Gamunex (AE, CY, ID, IL);</li>\n      <li>Gamunex C (SG);</li>\n      <li>Gamunex-C (HK, MY, TH);</li>\n      <li>Globuman Berna (PH);</li>\n      <li>Hizentra (AR, AT, AU, BE, BR, CH, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HR, HU, IE, JP, LB, LT, LU, NL, NO, NZ, PE, PL, PT, RO, SE, TR);</li>\n      <li>Humaglobin (VN);</li>\n      <li>Humoglob (PH);</li>\n      <li>I.V.-Globulin SN (PH);</li>\n      <li>IG Gamma (IL);</li>\n      <li>IG Vena (HK, PH);</li>\n      <li>Ig Vena NIV (ID);</li>\n      <li>Immunorel (PH);</li>\n      <li>Intragam P (AU, HK, ID);</li>\n      <li>Intraglobin (CH, DE, IT, TW);</li>\n      <li>Intraglobin F (IL);</li>\n      <li>Intratect (GB, HK, ID);</li>\n      <li>IV Globulin-S (KR);</li>\n      <li>Kiovig (AT, AU, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, HK, HN, IE, IL, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);</li>\n      <li>Klovig (TH);</li>\n      <li>Octagam (AT, AU, BE, BG, BH, BR, CH, CO, CZ, DE, DK, EE, FI, FR, GB, GR, HR, ID, IN, LB, LT, MT, MX, MY, NL, NO, NZ, PH, PL, RO, SA, SE, SI, SK, TH, UY, VN);</li>\n      <li>Pentaglobin (AT, DE, SG, TH, VN);</li>\n      <li>Privigen (IL);</li>\n      <li>Sandoglobulin (AE, BH, CZ, DK, EG, FI, GR, IL, KW, LB, LK, NO, NZ, PK, QA);</li>\n      <li>Sandoglobulina (CO, IT, PE);</li>\n      <li>Subcuvia (FR, GB);</li>\n      <li>Subgam (GB, IE);</li>\n      <li>Tegeline (LB);</li>\n      <li>Vena IG (LK);</li>\n      <li>Vigam (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abougergi MS and Kwon JH, &quot;Intravenous Immunoglobulin for the Treatment of <i>Clostridium difficile</i> Infection: A Review,&quot; <i>Dig Dis Sci</i>, 2011, 56(1):19-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/20924675/pubmed\" target=\"_blank\" id=\"20924675\">20924675</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Advisory Committee on Immunization Practices (ACIP), Fiore AE, Wasley A, et al, &quot;Prevention of Hepatitis A Through Active or Passive Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP),&quot; <i>MMWR Recomm Rep</i>, 2006, 55(RR-7):1-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/16708058/pubmed\" target=\"_blank\" id=\"16708058\">16708058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Subcommittee on Hyperbilirubinemia, &quot;Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation,&quot; <i>Pediatrics</i>, 2004, 114(1):297-316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/15231951/pubmed\" target=\"_blank\" id=\"15231951\">15231951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists&rsquo; Committee on Practice Bulletins&mdash;Obstetrics. Practice Bulletin No. 166: Thrombocytopenia in Pregnancy. <i>Obstet Gynecol</i>. 2016;128(3):e43-e53. doi: 10.1097/AOG.0000000000001641.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/27548554/pubmed\" target=\"_blank\" id=\"27548554\">27548554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson D, Ali K, Blanchette V, et al, &quot;Guidelines on the Use of Intravenous Immune Globulin for Hematologic Conditions,&quot; <i>Transfus Med Rev</i>, 2007, 21(2 Suppl 1):9-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/17397769/pubmed\" target=\"_blank\" id=\"17397769\">17397769</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASHP Commission on Therapeutics, &quot;ASHP Therapeutic Guidelines for Intravenous Immune Globulin,&quot; <i>Am J Hosp Pharm</i>, 1992, 49(3):652-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/1598949/pubmed\" target=\"_blank\" id=\"1598949\">1598949</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bassan H and Spirer Z, &quot;Intravenous Immunoglobulin in Neonatal Myasthenia Gravis,&quot; <i>J Pediatr</i>, 1999, 135(6):790.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/10586190/pubmed\" target=\"_blank\" id=\"10586190\">10586190</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bassan H, Muhlbaur B, Tomer A, et al, &quot;High-Dose Intravenous Immunoglobulin in Transient Neonatal Myasthenia Gravis,&quot; <i>Pediatr Neurol</i>, 1998, 18(2):181-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/9535308/pubmed\" target=\"_blank\" id=\"9535308\">9535308</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bivigam (immune globulin intravenous [human]) [prescribing information]. Boca Raton, FL: Biotest Pharmaceuticals Corp; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blanchette VS, Luke B, Andrew M, et al, &quot;A Prospective Randomized Trial of High-Dose Intravenous Immune Globulin G Therapy, Oral Prednisone Therapy, and No Therapy in Childhood Acute Immune Thrombocytopenic Purpura,&quot; <i>J Pediatr</i>, 1993, 123(6):989-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/8229536/pubmed\" target=\"_blank\" id=\"8229536\">8229536</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. <i>Ann Allergy Asthma Immunol</i>. 2005;94(5 Suppl 1):S1-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/15945566/pubmed\" target=\"_blank\" id=\"15945566\">15945566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    British Committee for Standards in Haematology General Haematology Task Force, &quot;Guidelines for the Investigation and Management of Idiopathic Thrombocytopenic Purpura in Adults, Children and in Pregnancy,&quot; <i>Br J Haematol</i>, 2003, 120(4):574-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/12588344/pubmed\" target=\"_blank\" id=\"12588344\">12588344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carimune (immune globulin intravenous [human]) [prescribing information]. Kankakee, IL: CSL Behring AG; September 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2006;55(RR-7):1-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/16708058/pubmed\" target=\"_blank\" id=\"16708058\">16708058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013: Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP),&quot; <i>MMWR Recomm Rep</i>, 2013;62(RR-04):1-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/23760231/pubmed\" target=\"_blank\" id=\"23760231\">23760231</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Updated dosing instructions for immune globulin (human) GamaSTAN S/D for hepatitis A virus prophylaxis. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(36):959-960.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/28910270/pubmed\" target=\"_blank\" id=\"28910270\">28910270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Update: Prevention of Hepatitis A After Exposure to Hepatitis A Virus and in International Travelers. Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP),&quot; <i>MMWR Morb Mortal Wkly Rep</i>, 2007, 56(41):1080-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/17947967/pubmed\" target=\"_blank\" id=\"17947967\">17947967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cherin P and Herson S, &quot;Indications for Intravenous Gammaglobulin Therapy in Inflammatory Myopathies,&quot; <i>J Neurol Neurosurg Psychiatry</i>, 1994, (57): 50-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/7964854/pubmed\" target=\"_blank\" id=\"7964854\">7964854</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cuvitru (immune globulin subcutaneous [human]) [prescribing information]. Westlake Village, CA: Baxalta US Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dalakas MC and Hohlfeld R, &quot;Polymyositis and Dermatomyositis,&quot; <i>Lancet</i>, 2003, 362(9388):971-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/14511932/pubmed\" target=\"_blank\" id=\"14511932\">14511932</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dalakas MC, Illa I, Dambrosia JM, et al, &quot;A Controlled Trial of High-Dose Intravenous Immune Globulin Infusions as Treatment for Dermatomyositis,&quot; <i>N Engl J Med</i>, 1993, 329(27):1993-2000.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/8247075/pubmed\" target=\"_blank\" id=\"8247075\">8247075</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dalakas MC, &quot;Intravenous Immunoglobulin In Autoimmune Neuromuscular Diseases,&quot; <i>JAMA</i>, 2004, 291(19):2367-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/15150209/pubmed\" target=\"_blank\" id=\"15150209\">15150209</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drucker NA, Colan SD, Lewis AB, et al, &quot;Gamma-Globulin Treatment of Acute Myocarditis in the Pediatric Population,&quot; <i>Circulation</i>, 1994, 89(1):252-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/8281654/pubmed\" target=\"_blank\" id=\"8281654\">8281654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barr&eacute; syndrome: a randomized study. <i>Crit Care</i>. 2011;15(4):R164.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eijkhout HW, van Der Meer JW, Kallenberg CG, et al, &quot;The Effect of Two Different Dosages of Intravenous Immunoglobulin on the Incidence of Recurrent Infections In Patients With Primary Hypogammaglobulinemia. A Randomized, Double-Blind, Multicenter Crossover Trial,&quot;<i> Ann Intern Med</i>, 2001, 135(3):165-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/11487483/pubmed\" target=\"_blank\" id=\"11487483\">11487483</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    English RF, Janosky JE, Ettedgui JA, et al, &quot;Outcomes for Children With Acute Myocarditis,&quot; <i>Cardiol Young</i>, 2004, 14(5):488-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/15680069/pubmed\" target=\"_blank\" id=\"15680069\">15680069</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FDA Safety Communication: updated information on the risks of thrombosis and hemolysis potentially related to administration of intravenous, subcutaneous and intramuscular human immune globulin products. November, 13, 2012. Available at <a href=\"http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm327934.htm?source=govdelivery%20ljb%20\" target=\"_blank\">http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm327934.htm?source=govdelivery ljb </a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feasby T, Banwell B, Benstead T, et al, &quot;Guidelines on the Use of Intravenous Immune Globulin for Neurologic Conditions,&quot; <i>Transfus Med Rev</i>, 2007, 21(2 Suppl 1):57-107.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/17397768/pubmed\" target=\"_blank\" id=\"17397768\">17397768</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flebogamma 5% DIF (immune globulin intravenous [human]) [prescribing information]. Barcelona, Spain: Instituto Grifols, SA; April 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flebogamma 10% DIF (immune globulin intravenous [human]) [prescribing information]. Los Angeles, CA: Grifols Biologicals Inc; September 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    GamaSTAN S/D (immune globulin intravenous [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gammagard Liquid (immune globulin intravenous [human]) [prescribing information]. Westlake Village, CA: Baxter Healthcare Corporation; September 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gammagard S/D 1 mcg (immune globulin intravenous [human]) [prescribing information]. Deerfield, IL: Baxter Healthcare Corp; September 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gammagard S/D 2.2 mcg (immune globulin intravenous [human]) [prescribing information]. Deerfield, IL: Baxter Healthcare Corp; September 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gammaked (immune globulin intravenous [human]) [prescribing information]. Fort Lee, NJ: Kedrion Biopharma, Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gammaplex 5% (immune globulin intravenous [human]) [prescribing information]. Raleigh, NC: BPL, Inc; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gammaplex 10% (immune globulin intravenous [human]) [prescribing information]. Raleigh, NC: BPL, Inc; 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gamunex-C (immune globulin intravenous [human]) [prescribing information]. Research Triangle Park, NC: Talecris Biotherapeutics; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gershon AA, Piomelli S, Karpatkin M, Smithwick E, Steinberg S. Antibody to varicella-zoster virus after passive immunization against chickenpox. <i>J Clin Microbiol</i>. 1978;8(6):733-735.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/217893/pubmed\" target=\"_blank\" id=\"217893\">217893</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Girish G, Chawla D, Agarwal R, et al, &quot;Efficacy of Two Dose Regimes of Intravenous Immunoglobulin in Rh Hemolytic Disease of Newborn--a Randomized Controlled Trial,&quot; <i>Indian Pediatr</i>, 2008, 45(8):653-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/18723908/pubmed\" target=\"_blank\" id=\"18723908\">18723908</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gottstein R and Cooke RW, &quot;Systematic Review of Intravenous Immunoglobulin in Haemolytic Disease of the Newborn,&quot; <i>Arch Dis Child Fetal Neonatal Ed</i>, 2003, 88(1):F6-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/12496219/pubmed\" target=\"_blank\" id=\"12496219\">12496219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gurcan HM and Ahmed AR, &quot;Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory Disorders,&quot; <i>Ann Pharmacother</i>, 2007, 41(5):812-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/17440006/pubmed\" target=\"_blank\" id=\"17440006\">17440006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections (OIs) in HIV-Exposed and HIV-Infected Children. December 2016. Available at <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hia CP, Yip WC, Tai BC, et al, &quot;Immunosuppressive Therapy in Acute Myocarditis: An 18 Year Systematic Review,&quot; <i>Arch Dis Child</i>, 2004, 89(6):580-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/15155409/pubmed\" target=\"_blank\" id=\"15155409\">15155409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hizentra (immune globulin intravenous [human]) [prescribing information]. Kankakee, IL: CSL Behring AG; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hughes RA, Raphael JC, Swan AV, et al, &quot;Intravenous Immunoglobulin for Guillain-Barre Syndrome,&quot; <i>Cochrane Database of Systematic Reviews</i>, 2008, issue 2.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hughes RA, Wijdicks EF, Barohn R, et al, &quot;Practice Parameter: Immunotherapy for Guillain-Barr&eacute; Syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology,&quot; <i>Neurology</i>, 2003, 61(6):736-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/14504313/pubmed\" target=\"_blank\" id=\"14504313\">14504313</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HyQvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) [prescribing information]. Westlake Village, CA: Baxter Healthcare Corporation; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    INIS Collaborative Group, Brocklehurst P, Farrell B, et al, &quot;Treatment of Neonatal Sepsis With Intravenous Immune Globulin,&quot; <i>N Engl J Med</i>, 2011, 365(13):1201-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/21962214/pubmed\" target=\"_blank\" id=\"21962214\">21962214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jenson HB and Pollock BH, &quot;Meta-Analyses of the Effectiveness of Intravenous Immune Globulin for Prevention and Treatment of Neonatal Sepsis,&quot; <i>Pediatrics</i>, 1997, 99(2):E2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/9099759/pubmed\" target=\"_blank\" id=\"9099759\">9099759</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klugman D, Berger JT, Sable CA, et al, &quot;Pediatric Patients Hospitalized With Myocarditis: A Multi-institutional Analysis,&quot; <i>Pediatr Cardiol</i>, 2010, 31(2):222-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/19936586/pubmed\" target=\"_blank\" id=\"19936586\">19936586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koh MJ and Tay YK, &quot;Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Asian Children,&quot; <i>J Am Acad Dermatol</i>, 2010, 62(1):54-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/19811851/pubmed\" target=\"_blank\" id=\"19811851\">19811851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Korinthenberg R, Schessl J, Kirschner J, M&ouml;nting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barr&eacute; syndrome: a randomized trial. <i>Pediatrics</i>. 2005;116(1):8-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/15995024 /pubmed\" target=\"_blank\" id=\"15995024 \">15995024 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuwabara S, &quot;Guillain-Barr&eacute; Syndrome: Epidemiology, Pathophysiology and Management,&quot; <i>Drugs</i>, 2004, 64(6):597-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/15018590/pubmed\" target=\"_blank\" id=\"15018590\">15018590</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leung DY, Kelly CP, Boguniewicz M, et al, &quot;Treatment With Intravenously Administered Gamma Globulin of Chronic Relapsing Colitis Induced by <i>Clostridium difficile</i> Toxin,&quot; <i>J Pediatr</i>, 1991, 118(4 Pt 1):633-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/1901084/pubmed\" target=\"_blank\" id=\"1901084\">1901084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki Disease: a scientific statement for health professionals from the American Heart Association. <i>Circulation</i>. 2017;135(17):e927-e999.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/28356445/pubmed\" target=\"_blank\" id=\"28356445\">28356445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McFarland LV, Brandmarker SA, and Guandalini S, &quot;Pediatric <i>Clostridium difficile</i>: A Phantom Menace or Clinical Reality?&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2000, 31(3):220-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/10997362/pubmed\" target=\"_blank\" id=\"10997362\">10997362</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miqdad AM, Abdelbasit OB, Shaheed MM, et al, &quot;Intravenous Immunoglobulin G (IVIG) Therapy for Significant Hyperbilirubinemia in ABO Hemolytic Disease of the Newborn,&quot; <i>J Matern Fetal Neonatal Med</i>, 2004, 16(3):163-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/15590442/pubmed\" target=\"_blank\" id=\"15590442\">15590442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morici MV, Galen WK, Shetty AK, et al, &quot;Intravenous Immunoglobulin Therapy for Children With Stevens-Johnson Syndrome,&quot; <i>J Rheumatol</i>, 2000, 27(10):2494-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/11036849/pubmed\" target=\"_blank\" id=\"11036849\">11036849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. <i>Blood</i>. 2011;117(16):4190-4207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/21325604/pubmed\" target=\"_blank\" id=\"21325604\">21325604</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Newburger JW, Takahashi M, Gerber MA, et al, &quot;Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association,&quot; <i>Pediatrics</i>, 2004, 114(6):1708-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/15574639/pubmed\" target=\"_blank\" id=\"15574639\">15574639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NIH Consensus Conference, &quot;Intravenous Immunoglobulin, Prevention and Treatment of Disease,&quot; <i>JAMA</i>, 1990, 264(24):3189-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/2255028/pubmed\" target=\"_blank\" id=\"2255028\">2255028</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Octagam (immune globulin intravenous [human]) [prescribing information]. Hoboken, NJ: Octapharma USA Inc; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Octagam 10% (immune globulin intravenous [human]) [prescribing information]. Hoboken, NJ: Octapharma USA; April 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohlsson A and Lacy J, &quot;Intravenous Immunoglobulin for Suspected or Subsequently Proven Infection in Neonates,&quot; <i>Cochrane Database Syst Rev</i>, 2010, (3):CD001239.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/20238315/pubmed\" target=\"_blank\" id=\"20238315\">20238315</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patwa HS, Chaudhry V, Katzberg H, et al, &quot;Evidence-Based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromuscular Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology,&quot; <i>Neurology</i>, 2012, 78(13):1009-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/22454268/pubmed\" target=\"_blank\" id=\"22454268\">22454268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Privigen (immune globulin intravenous [human]) [prescribing information]. Kankakee, IL: CSL Behring AG; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sansome A and Dubowitz V, &quot;Intravenous Immunoglobulin in Juvenile Dermatomyositis--Four Year Review of Nine Cases,&quot; <i>Arch Dis Child</i>, 1995, 72(1):25-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/7717731/pubmed\" target=\"_blank\" id=\"7717731\">7717731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siegel J, &quot;Immune Globulins: Therapeutic, Pharmaceutical, Cost and Administration Considerations,&quot; <i>Pharmacy Practice News</i>, 2011, 20-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siegel J, &quot;Immunoglobulins and Obesity,&quot; <i>Pharmacy Practice News</i>, 2010, 37:1.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tagher RJ, Baumann R, and Desai N, &quot;Failure of Intravenously Administered Immunoglobulin in the Treatment of Neonatal Myasthenia Gravis,&quot; <i>J Pediatr</i>, 1999, 134(2):233-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/9931536/pubmed\" target=\"_blank\" id=\"9931536\">9931536</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomblyn M, Chiller T, Einsele H, et al, &quot;Guidelines for Preventing Infectious Complications Among Hematopoietic Cell Transplantation Recipients: A Global Perspective,&quot; <i>Biol Blood Marrow Transplant</i>, 2009, 15(10):1143-238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/19747629/pubmed\" target=\"_blank\" id=\"19747629\">19747629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tristani-Firouzi P, Petersen MJ, Saffle JR, et al, &quot;Treatment of Toxic Epidermal Necrolysis With Intravenous Immunoglobulin in Children,&quot; <i>J Am Acad Dermatol</i>, 2002, 47(4):548-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/12271299/pubmed\" target=\"_blank\" id=\"12271299\">12271299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations Consensus Statement,&quot; <i>JAMA</i>, 1995, 273(23):1865-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/7776504/pubmed\" target=\"_blank\" id=\"7776504\">7776504</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watson JC, Hadler SC, Dykewicz CA, et al, &quot;Measles, Mumps, and Rubella &minus; Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP),&quot; <i>MMWR Recomm Rep</i>, 1998, 47(RR-8):1-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information/abstract-text/9639369/pubmed\" target=\"_blank\" id=\"9639369\">9639369</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wimperis J, Lunn M, Jones A, et al, &quot;National Health Service. Clinical Guidelines for the Use of Immunoglobulin Use: Second Edition Update, July 2011.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 83878 Version 153.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F11513229\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F11513233\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F11513234\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F13307640\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F13307724\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F13307648\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F11513299\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F11513236\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F26116456\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F13307649\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F11513261\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13307641\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F11513231\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F11513251\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F11513246\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F11513247\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299513\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F11513254\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F11513243\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F11513244\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13307650\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F11513265\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F11513267\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F13307652\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322887\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059490\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/83878|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information</a></li><li><a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-patient-drug-information\" class=\"drug drug_patient\">Immune globulin (Intravenous, subcutaneous, and intramsucular): Patient drug information \t</a></li></ul></div></div>","javascript":null}